Research analysts at FinnCap initiated coverage on shares of ImmuPharma (LON:IMM) in a note issued to investors on Tuesday. The brokerage set a “buy” rating and a GBX 237 ($3.19) price target on the stock. FinnCap’s price target suggests a potential upside of 40.83% from the stock’s previous close.
A number of other equities research analysts also recently issued reports on the stock. Northland Securities reaffirmed a “buy” rating and issued a GBX 181 ($2.44) price objective on shares of ImmuPharma in a research report on Thursday, November 2nd. Northland Capital Partners reaffirmed a “buy” rating and issued a GBX 181 ($2.44) price objective on shares of ImmuPharma in a research report on Thursday, September 21st.
Shares of ImmuPharma (IMM) opened at GBX 168.29 ($2.26) on Tuesday. ImmuPharma has a 52-week low of GBX 36 ($0.48) and a 52-week high of GBX 175.35 ($2.36).
ImmuPharma Company Profile
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.